Integration of Biologic Agents With Cytotoxic Chemotherapy in Metastatic Colorectal Cancer
- 31 December 2011
- journal article
- review article
- Published by Elsevier BV in Clinical Colorectal Cancer
- Vol. 10 (4), 245-257
- https://doi.org/10.1016/j.clcc.2011.04.001
Abstract
No abstract availableKeywords
This publication has 98 references indexed in Scilit:
- Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapyBritish Journal of Cancer, 2011
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysisThe Lancet Oncology, 2010
- Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trialThe Lancet Oncology, 2010
- Treatment in advanced colorectal cancer: what, when and how?British Journal of Cancer, 2009
- Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trialThe Lancet, 2008
- Predictors of survival after hepatic resection among patients with colorectal liver metastasisBritish Journal of Cancer, 2007
- First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first‐line treatment for metastatic colorectal cancerCancer, 2007
- Safe liver resection following chemotherapy for colorectal metastases is a matter of timingBritish Journal of Cancer, 2007
- The biology of VEGF and its receptorsNature Medicine, 2003
- Five-Year Survival Following Hepatic Resection After Neoadjuvant Therapy for Nonresectable Colorectal [Liver] MetastasesAnnals of Surgical Oncology, 2001